Mankind Pharma: Q2 FY27 revenue up 17% as EBITDA margins expand to 27.1%
FROM THE WIRE · GURUFOCUS.COM
Revenue: INR4,338 crores in Q2 FY27, up 17.3% YoY from INR3,697 crores in Q2 FY26.Domestic Revenue (ex-Consumer Healthcare): INR3,428 crores, up 15.9% YoY.Domes
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishDouble-digit revenue growth with expanding margins is a positive signal for the stock in India's pharma sector.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Revenue reached INR4,338 crores in Q2 FY27, up 17.3% YoY from INR3,697 crores.
- 02Domestic revenue excluding Consumer Healthcare was INR3,428 crores, up 15.9% YoY.
- 03EBITDA margin expanded to 27.1%.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets